Natixis’s CG Oncology CGON Stock Holding History

Natixis’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,437	Closed	-$501K	–	1148
2025 Q3	$501K	Buy	+12,437	New	+$362K	﹤0.01%	785

Other funds holding CGON

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Natixis's CGON Position: Q4 2025 in Review

Natixis sold out of CG Oncology (CGON) in Q4 2025, closing a stake of 12,437 shares — an estimated $501K sold.

Natixis first reported a position in CGON in Q3 2025 and held it in 1 quarter. The position peaked at $501K in Q3 2025. 195 funds tracked by Wall St. Rank hold CGON as of Q4 2025.

Natixis reported no remaining CG Oncology position as of Q4 2025 after selling out during the quarter.
Natixis sold 12,437 CG Oncology shares in Q4 2025, an estimated $501K.
Natixis first reported a position in CG Oncology in Q3 2025 and held it in 1 quarter.
Natixis's CG Oncology position peaked at $501K in Q3 2025.
195 funds tracked by Wall St. Rank held CG Oncology as of Q4 2025.

Based on Natixis's 13F filing for Q4 2025, filed 13 Feb 2026.